Kexon Pharmaceuticals announced that the company will hold the third extraordinary shareholders' meeting on December 31, 2025 to review the two proposals. First, it is proposed that the “Pharmaceutical Production Base Renovation and Expansion Project” raise capital of 109.1522 million yuan and proceeds of 15.867,800 yuan for the “R&D Center Upgrade and Construction Project”. The total amount raised for the project will be increased to 472.4824 million yuan, and the implementation period will be extended until December 31, 2028. Second, it is proposed to re-hire Tongtong Accounting Firm as the audit agency for the year 2025. The audit fee for 2025 is 1.3 million yuan, which is the same as 2024.

Zhitongcaijing · 3d ago
Kexon Pharmaceuticals announced that the company will hold the third extraordinary shareholders' meeting on December 31, 2025 to review the two proposals. First, it is proposed that the “Pharmaceutical Production Base Renovation and Expansion Project” raise capital of 109.1522 million yuan and proceeds of 15.867,800 yuan for the “R&D Center Upgrade and Construction Project”. The total amount raised for the project will be increased to 472.4824 million yuan, and the implementation period will be extended until December 31, 2028. Second, it is proposed to re-hire Tongtong Accounting Firm as the audit agency for the year 2025. The audit fee for 2025 is 1.3 million yuan, which is the same as 2024.